Market Movers: Nike, Nvidia, Vanda

Kim Kahn notes Nike CEO share purchase, Nvidia's H200 demand, and FDA approval boosting Vanda Pharmaceuticals stock.

Play episode from 02:10

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!